{"id":2891,"date":"2016-12-07T17:54:06","date_gmt":"2016-12-07T17:54:06","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=18646"},"modified":"2016-12-07T17:54:06","modified_gmt":"2016-12-07T17:54:06","slug":"medical-marijuana-inc-s-investment-company-aximr-biotech-receives-approval-medical-ethical-committee-begin-ibs-trial-cbd-product","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/12\/07\/medical-marijuana-inc-s-investment-company-aximr-biotech-receives-approval-medical-ethical-committee-begin-ibs-trial-cbd-product\/","title":{"rendered":"Medical Marijuana, Inc.’s Investment Company AXIM\u00ae Biotech Receives Approval From Medical Ethical Committee to Begin IBS Trial for CBD Product"},"content":{"rendered":"

SAN DIEGO, CA –(Marketwired – December 06, 2016) – <\/span>Medical Marijuana, Inc.<\/span> (OTC PINK: MJNA), the world’s leading cannabis portfolio company and first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM\u00ae Biotechnologies, Inc.<\/a> (AXIM\u00ae Biotech) (OTC PINK: AXIM)received approval from the Medical Ethical Committee (METC) of Wageningen University in The Netherlands to begin a study on patients suffering from irritable bowel syndrome (IBS) with the AXIM’s product CanChew Plus\u00ae CBD-containing chewing gum.<\/span><\/p>\n

“We congratulate AXIM on yet another step forward toward full clinical trials on cannabis-based treatments,” said Dr. Stuart Titus, CEO of Medical Marijuana Inc. “With the global treatment market for irritable bowel syndrome <\/span>estimated to grow in value to $1.5 billion by 2023<\/span><\/a>, cannabis-based products like CanChew Plus\u00ae can provide viable solutions for patients suffering from some of the most common of functional gastrointestinal disorders.”<\/span><\/p>\n

“It is the goal of our family of companies and for AXIM to help people suffering from various gastrointestinal disorders with no effective remedies such as IBD and Crohn’s disease. Positive outcomes from these type of studies can help in the immediate need to enter trials for inflammatory bowel disease (IBD) and Crohn’s disease.”<\/span><\/p>\n

METC at Wageningen University is an institutional approval board that is compliant with the Ethical Principles for Medical Research adopted at the 18th World Medical Association (WMA) General Assembly in Helsinki, Finland, in June 1964.<\/span><\/p>\n

Wageningen University is a world-class education and research institute in the field of life sciences, agricultural and environmental science, and the only university in The Netherlands to focus on the theme of “healthy food and living environment.” According to the Times Higher Education World University Rankings, Wageningen is <\/span>the best university in The Netherlands<\/span><\/a> and No. 1 worldwide in agriculture and forestry for 2016 on the QS World University Rankings.<\/span><\/p>\n

About Medical Marijuana, Inc.<\/strong><\/p>\n

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit <\/span>www.medicalmarijuanainc.com<\/span><\/a>.<\/span><\/p>\n

To see Medical Marijuana, Inc.’s video statement, <\/span>click here<\/span><\/a>. Shareholders are also encouraged to visit the <\/span>Medical Marijuana, Inc. Shop<\/span><\/a> for discounted products.<\/span><\/p>\n

About AXIM\u00ae<\/strong><\/p>\n

AXIM\u00ae Biotechnologies, Inc. (OTC PINK: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew\u00ae, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD\/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit <\/span>www.AXIMBiotech.com<\/span><\/a>.<\/span><\/p>\n

About CanChew\u00ae and CanChew Plus\u00ae<\/span><\/p>\n

CanChew<\/span><\/a>\u00ae is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew\u00ae website include:<\/span><\/p>\n